In-vitro activity of the synthetic protegrin IB-367 alone and in combination with antifungal agents against clinical isolates of Candida spp

J Chemother. 2007 Oct;19(5):514-8. doi: 10.1179/joc.2007.19.5.514.

Abstract

The in vitro activity of the peptide IB-367, alone or combined with either fluconazole (FLU) or amphotericin B (AMB), was investigated against 25 Candida isolates belonging to five species. IB-367 minimum inhibitory concentrations (MICs) ranged from 2.0 to 32 microg/ml and it was active against both FLU-susceptible and - resistant isolates. A rapid fungicidal activity was observed. Synergism was documented in 41.6% and 44% of IB-367/FLU and IB-367/AMB interactions, respectively. Antagonism was never observed. The broad antifungal activity and the positive interactions with AMB and FLU suggest that IB-367 represents a promising candidate against infections due to Candida spp.

MeSH terms

  • Amphotericin B / administration & dosage
  • Antifungal Agents / pharmacology*
  • Antimicrobial Cationic Peptides
  • Candida / drug effects*
  • Candidiasis / drug therapy
  • Drug Resistance, Fungal
  • Drug Synergism
  • Drug Therapy, Combination
  • Fluconazole / administration & dosage
  • Humans
  • In Vitro Techniques
  • Microbial Sensitivity Tests
  • Peptides / pharmacology*

Substances

  • Antifungal Agents
  • Antimicrobial Cationic Peptides
  • Peptides
  • Amphotericin B
  • Fluconazole
  • antimicrobial peptide IB-367